Hyperphosphatemia is a condition that means you have high levels of phosphorus in your body. It can happen due to your diet or a change in your kidneys’ function. Often, hyperphosphatemia has no ...
Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
As a physician and researcher caring for people with chronic kidney disease, I see firsthand the challenges that patients undergoing dialysis face. Dialysis is life-sustaining, but it also brings ...
June 30 (Reuters) - Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to treat ...
DUBAI, United Arab Emirates, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Future Market Insights estimates that the Hyperphosphatemia Market will experience a rapid expansion between the years 2023 and 2033. By ...
A research team from Argentina prospectively studied the frequency of hyperphosphatemia following the administration of oral sodium phosphate (OSP) in low-risk patients. They found that the standard ...
Please provide your email address to receive an email when new articles are posted on . Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased ...
Hyperphosphatemia is excess phosphate in the blood, most often caused by kidney disease that prevents the kidneys from removing enough phosphate. Other causes include unmanaged diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results